PCRX — PACIRA BIOSCIENCES, INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
PCRX FAQ
What is PCRX's P/E ratio?
PACIRA BIOSCIENCES, INC. (PCRX) currently trades at a P/E ratio of 89.65.
What is PCRX's ROE?
PACIRA BIOSCIENCES, INC. reports a Return on Equity (ROE) of 0.79%.
What is PCRX's dividend yield?
PACIRA BIOSCIENCES, INC. offers a dividend yield of 0.00%.
What is PCRX's Deepscope Quality Score?
Deepscope rates PCRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PCRX?
Deepscope's AI Timing Score for PCRX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PCRX belong to?
PACIRA BIOSCIENCES, INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 22.86
Price
0.11
(0.48%)
Day Change
|
|
|---|
PCRX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
3069
|
| Magic Formula Rank by ROE |
3069
|
| Magic Formula Rank by ROIC |
2962
|
| Price | 22.86 |
| PBV / Sector |
1.37 / 2.63
GOOD
|
| Earning Per Share | 0.13 |
| PE / Sector |
89.65 / 23.62
|
| PEG or PE/Growth / Sector |
-0.80 / 0.12
|
| Average 1M Daily Value |
9.97 M
|
| Average 1W Daily Value |
7.70 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-09 09:39:47 |
| Symbol | PCRX |
| Name | PACIRA BIOSCIENCES, INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 39.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 895.17 / 9,799.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone: 650 242 8052
Website: https://www.pacira.com
Employees: 825
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google